A noninvasive enhanced liver fibrosis blood test identifies patients with nonalcoholic fatty liver disease who are at increased risk of advanced fibrosis, according to a new study.
A case report of life-threatening hepatitis in a lung cancer patient suggests caution when using second-line sotorasib in patients previously treated with checkpoint inhibitors.
A combination of MRE and FIB-4 outperformed FAST in determining the presence of significant fibrosis among patients with NAFLD, according to a prospective cohort analysis.